Karen Basu
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.
Journal: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Published: April 19, 2024
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.
Journal: Ophthalmology science
Published: October 29, 2022
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Journal: Lancet (London, England)
Published: August 31, 2021
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Journal: Lancet (London, England)
Published: August 31, 2021
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology science
Published: June 11, 2021
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Journal: Ophthalmology science
Published: June 11, 2021
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: July 31, 2020
Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
Journal: Ophthalmology. Retina
Published: April 21, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026